卵巢癌肿瘤分子标记物联合动态监测的研究与临床应用  

Research and clinical application of combined dynamic monitoring of tumor marker for ovarian cancer

作　　者：王清华[1] 徐风亮[1] 许祯杰[1] 

机构地区：[1]山东省日照市人民医院,276826

出　　处：《中国临床实用医学》2014年第4期24-26,共3页China Clinical Practical Medicine

摘　　要：目的：探讨血清肿瘤分子标记物糖类抗原（CA125）、癌胚抗原（CEA）、人附睾蛋白4（HE4）、恶性肿瘤特异性生长因子（TSGF）联合动态监测诊断卵巢癌的临床应用价值。方法选取2011年1月至2013年12月日照市人民医院收治的100例卵巢癌患者作为观察组，另选30例卵巢良性病变患者作为对照组，两组患者均经术后病理学确诊。采用电化学发光法检测患者血清 CA125、CEA，ELISA 法检测 HE4，化学比色法检测 TSGF 水平，分析血清肿瘤分子标记物与卵巢良恶性肿瘤的相关性。结果观察组患者血清 CA125、CEA、HE4、TSGF 水平明显高于对照组（P<0.01）；卵巢癌高分期组（Ⅲ、Ⅳ期）明显高于低分期组（Ⅰ、Ⅱ期），淋巴结转移明显高于无转移者，复发者明显高于无复发者（均 P<0.01）；术后1周明显低于术前（P<0.01）；4项肿瘤分子标记物联合检测诊断卵巢癌的敏感性、准确性、阴性预测值明显高于单项检测（P<0.01）。结论血清 CA125、CEA、HE4、TSGF 水平与卵巢癌临床分期、复发及转移相关，联合检测可提高卵巢癌诊断的敏感性、准确性、阴性预测值，同时联合动态监测对监控治疗、复发、转移及随访具有临床指导意义。Objective Explore the clinical value of serum tumor markers,such as carbohydrate antigens(CA125), carcinoembryonic antigen(CEA), human epididymis protein 4 (HE4), malignant tumor specific growth factor (TSGF),combined with dynamic monitoring for the diagnosis of ovarian cancer. Methods From January 2011 to December 2013,100 cases of ovarian cancer patients (observation group) and 30 cases of patients with ovarian benign lesions (control group) were selectd as the research object, both of them by postoperative pathological diagnosis.Electrochemical luminescence method to detect patients with serum CA125, CEA, ELISA method for detecting HE4, chemical colorimetry to detect levels of TSGF, then analyse the correlation of ovarian benign and malignant tumors with serum levels of tumor molecular markers. Results CA125, CEA, HE4, TSGF level of ovarian cancer patients were obviously higher than that of ovarian benign tumor lesion group(P<0.01);Ovarian cancer is high ( Ⅲ , Ⅳ ) staging group was obviously higher than that of low stage group ( Ⅰ , Ⅱ ), lymph node metastasis were significantly higher than those without metastasis,recurrence were significantly higher than the relapse-free(P<0.01);One week after operation was significantly lower than that before operation(P<0.01);Four joint tumor molecular markers to detect the sensitivity and accuracy of the diagnosis of ovarian cancer, negative predictive value is significantly higher than individual test(P<0.01). Conclusion Serum CA125, CEA, HE4, TSGF levels associated with ovarian cancer clinical stage, recurrence and metastasis, the joint detection can improve the sensitivity and accuracy of the diagnosis of ovarian cancer, negative predictive value, at the same time,he joint dynamic monitoring to monitor treatment, recurrence and metastasis and follow-up have clinical significance.

关 键 词：卵巢癌 肿瘤分子标记物 联合动态检测 监控 

分 类 号：R[医药卫生]